William Eaves, MD
Cardiovascular Disease · Shreveport, LANPI 1801861240
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,764 of the $15,374 with a category attached, or 76.5%. 50 manufacturers reported payments, led by Boston Scientific at 39.5% of the total. Reporting peaked in 2019 at $5,701 and has fallen 60.6% since, to $2,245 in 2025.
Across 512 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Philips North America LLC$784
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$777
- Abiomed$759
- Pfizer$700
- Shockwave Medical, Inc$688
- plus $6K from 44 others
Across 883 payments — averaging $1859.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$398K
- Boehringer Ingelheim$333K
- Amgen$185K
- Janssen Research & Development, LLC$108K
- Boehringer Ingelheim International GmbH$96K
- Eli Lilly$85K
- plus $437K from 15 others
What the payments were for
- Consulting fees$3,50023%
- Food & beverage$11,76477%
- Education$1091%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANGIOJET$3,500
- WatchPat$387
- ELUVIA$229
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$224
- Assure WCD$159
- ZIO XT Patch$158
- Supera peripheral stent system$157
- Vascular Lithotripsy$156
- WatchPATONE$154
- AVVIGO Guidance System$146
- Ranger$138
- Impella$130
- VYNDAQEL$124
- IGT D Peripheral$121
- GENERAL VASCULAR INTERVENTION$113
- Torus Stent Graft System$107
- ENDOCROSS Device$107
- GENERAL BALLOONS$105
How this compares
$15,374 in reported general payments places this provider in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 354 | $300,485 |
| EntrestoSacubitril/Valsartan | 184 | $161,138 |
| BrilintaTicagrelor | 142 | $104,888 |
| JardianceEmpagliflozin | 82 | $71,229 |
| Repatha SureclickEvolocumab | 99 | $70,200 |
| XareltoRivaroxaban | 33 | $38,818 |
| OzempicSemaglutide | 30 | $30,109 |
| FarxigaDapagliflozin Propanediol | 38 | $25,493 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 260 | $5,210 |
| Metoprolol Succinate | 408 | $4,546 |
| Propafenone Hcl | 100 | $3,223 |
| Propafenone Hcl ErPropafenone Hcl | 13 | $3,111 |
| Ranolazine ErRanolazine | 19 | $2,964 |
| ClopidogrelClopidogrel Bisulfate | 336 | $2,655 |
| Atorvastatin Calcium | 227 | $2,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $700 | $300,485354 claims |
| NovartisEntresto | $507 | $161,138184 claims |
| AstraZenecaBrilinta, Farxiga | $351 | $130,381180 claims |
| Boehringer IngelheimJardiance | $189 | $71,22982 claims |
| Johnson & JohnsonXarelto | $42 | $38,81833 claims |
| Novo NordiskOzempic | $51 | $30,10930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Shreveport
- Basel KasabaliShreveport$30K
- Tina FirouzbakhtShreveport$28K
- Wenwu ZhangShreveport$21K
- Jagan BeedupalliShreveport$13K
- Mahin KhanShreveport$10K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.